Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Endocalyx, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose); Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Macular Degeneration
Interventions: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more

Conditions: Endothelial Dysfunction, Inflammation, Oxidative Stress
Interventions: Traditional hookah smoking, Electronic hookah vaping; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 39 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Failure
Interventions: LOVAZA (Omega-3), Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Living-Donor Kidney Transplants
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cataracts
Interventions: Standard phacoemulsification, Reduced ultrasound phacoemulsification; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Vascular Complications
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Erythritol; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endothelial Dysfunction
Interventions: Human albumin, Hydroxyethyl starch; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metabolic Syndrome
Interventions: Blend 1, Blend 2, Placebo; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
Interventions: Acarbose; Drug
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 25 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions: ABBV-RGX-314, Ranibizumab (LUCENTIS®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 89
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more

Conditions: Airway Inflammation
Interventions: placebo, Montelukast; Other · Drug
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Bevespi, Bretzri; Drug
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Age Related Macular Degeneration
Interventions: Ranibizumab, Bevacizumab, Aflibercept, Control Group; Drug · Other
Lead sponsor: East Florida Eye Institute; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stuart, Florida

Conditions: Healthy
Interventions: Berry extract, Placebo; Dietary Supplement · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Neovascular Age-related Macular Degeneration
Interventions: PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection); Device · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 40
States / cities: Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 36 more

Conditions: Myocardial Ischemia, Critical Illness, Endothelial Dysfunction
Interventions: Day Light, Placebo light, ICU Intense Light, ICU Placebo light; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Adverse Childhood Experiences, Endothelial Dysfunction
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions: Absorb BVS, XIENCE; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,008 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 190
States / cities: Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more

Conditions: Diabetes Mellitus, Type 2
Interventions: 20 million Allogeneic Mesenchymal Human Stem Cells, 100 million Allogeneic Mesenchymal Human Stem Cells; Drug
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Coronary Syndrome
Interventions: intensive LDL-lowering therapy, standard statin monotherapy; Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 31 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Dallas, Texas

Search by objective public record fields.

Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

The Cardiovascular Effects of Electronic Hookah Vaping

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

Correlation of Donor-specific Anti-endothelial Cells

Endothelial Cell Loss After Cataract Surgery

Continuous Glucose Monitoring in Type 2 Diabetes Mellitus

Dose-Dependent Effects of Erythritol on Endothelial Function in Type 2 Diabetes Mellitus

Endothelial Function After Cardiac Surgery

Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome

Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD

Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients

Impacts of a Combined Berry Extract Supplement on Vascular Function and Oxygen Utility Capacity in Young Adults

Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Bright Light Exposure in Surgical Patients

ACEs, SIRT1, and Premature Vascular Aging in Humans

ABSORB III Randomized Controlled Trial (RCT)

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I